Cristina Gasparetto | Scholars@Duke

Cristina Gasparetto
Professor of Medicine

Dr. Gasparetto performs both laboratory and clinical research in the field of multiple myeloma. Her primary research interests are in developing immunotherapy approaches to treating multiple myeloma particularly in conjunction with hematopoietic stem cell transplantation. Ongoing laboratory research projects include the development of dendritic cell vaccines and antibody therapies. Clinical studies include a recently approved trial involving vaccination with autologous dendritic cells pulsed with idiotypic protein following high dose chemotherapy and autologous peripheral blood stem cells transplant. Upcoming trials include novel antibody therapies for multiple myeloma. Dr. Gasparetto is also an investigator on several other clinical trials for myeloma including non-myeloablative allogeneic transplantation, high dose sequential chemotherapy and autologous peripheral blood stem cell transplantation and transplantation of partially HLA matched unrelated cord blood.

Current Appointments & Affiliations

Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2018
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1993

Contact Information

2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
DUMC Box 3961, Durham, NC 27710
gaspa001@mc.duke.edu (919) 668-1000

Background
Education, Training, & Certifications
- Fellow in Hematology/Oncology, Medicine, Duke University 1996 - 1999
- Medical Resident, Medicine, Duke University 1993 - 1996
- M.D., Sapienza University of Rome (Italy) 1986
Previous Appointments & Affiliations
- Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2012 - 2018
- Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2008 - 2012
- Assistant Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2002 - 2008
- Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1999 - 2002
- Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 1999
Research
Selected Grants
External Relationships
- AbbVie Pharmaceuticals
- AbbVie, Inc.
- Amgen, Inc.
- Astellas Pharma Inc.
- Brystol Myers (celgene)
- Gilead Sciences, Inc.
- GlaxoSmithKline
- Janssen AI (Johnson & Johnson)
- Karyopharm Therapeutics Inc
- Millennium Pharmaceuticals, Inc. (Takeda)
- Sanofi
- Seattle Genetics
- adaptive biotechnology corporation
- incyte
- oncopeptide
Publications & Artistic Works
Selected Publications
- Academic Articles
  - D’Souza, Anita, Ruta Brazauskas, Edward A. Stadtmauer, Marcelo C. Pasquini, Parameswaran Hari, Asad Bashey, Natalie Callander, et al. “Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.” Am J Hematol 98, no. 1 (January 2023): 140–47. https://doi.org/10.1002/ajh.26596.
    Full Text Link to Item
  - Kang, Yubin, Pasupathi Sundaramoorthy, Cristina Gasparetto, Daniel Feinberg, Shengjun Fan, Gwynn Long, Emily Sellars, et al. “Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.” Ann Hematol, December 3, 2022. https://doi.org/10.1007/s00277-022-05056-7.
    Full Text Link to Item
  - Lew, Meagan V., Yi Ren, Yen P. Lowder, Sharareh Siamakpour-Reihani, Sendhilnathan Ramalingam, Kristi M. Romero, Jillian C. Thompson, et al. “Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years.” Transplant Cell Ther 28, no. 8 (August 2022): 498.e1-498.e9. https://doi.org/10.1016/j.jtct.2022.05.018.
    Full Text Link to Item
  - Richardson, Paul G., Susanna J. Jacobus, Edie A. Weller, Hani Hassoun, Sagar Lonial, Noopur S. Raje, Eva Medvedova, et al. “Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.” N Engl J Med 387, no. 2 (July 14, 2022): 132–47. https://doi.org/10.1056/NEJMoa2204925.
    Full Text Link to Item
  - Sung, Anthony D., Vinay K. Giri, Helen Tang, Krista Rowe Nichols, Meagan V. Lew, Lauren Bohannon, Yi Ren, et al. “Home-Based Hematopoietic Cell Transplantation in the United States.” Transplant Cell Ther 28, no. 4 (April 2022): 207.e1-207.e8. https://doi.org/10.1016/j.jtct.2022.01.015.
    Full Text Link to Item
  - Gasparetto, Cristina, Gary J. Schiller, Sascha A. Tuchman, Natalie S. Callander, Muhamed Baljevic, Suzanne Lentzsch, Adriana C. Rossi, et al. “Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.” Br J Cancer 126, no. 5 (March 2022): 718–25. https://doi.org/10.1038/s41416-021-01608-2.
    Full Text Link to Item
  - Gasparetto, Cristina, Sundar Jagannath, Robert M. Rifkin, Brian G. M. Durie, Mohit Narang, Howard R. Terebelo, Kathleen Toomey, et al. “Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.” Clin Lymphoma Myeloma Leuk 22, no. 3 (March 2022): 149–57. https://doi.org/10.1016/j.clml.2021.08.007.
    Full Text Link to Item
  - Wu, Jian, Emily Chu, Cristiana Costa Chase, Taewoong Choi, Cristina Gasparetto, Ken Young, and Yubin Kang. “Anaplastic Multiple Myeloma: Case Series and Literature Review.” Asploro J Biomed Clin Case Rep 5, no. 1 (2022): 1–11. https://doi.org/10.36502/2022/asjbccr.6255.
    Full Text Link to Item
  - Gasparetto, Cristina, Kristian M. Bowles, Al-Ola Abdallah, Lura Morris, Gudrun Mander, Sheryl Coppola, Jing Wang, et al. “A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.” Clin Lymphoma Myeloma Leuk 21, no. 11 (November 2021): 775–84. https://doi.org/10.1016/j.clml.2021.07.029.
    Full Text Link to Item
  - Ramasamy, Karthik, Ajay Nooka, Hang Quach, Myo Htut, Rakesh Popat, Michaela Liedtke, Sascha A. Tuchman, et al. “A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.” Blood Cancer J 11, no. 9 (September 3, 2021): 149. https://doi.org/10.1038/s41408-021-00545-w.
    Full Text Link to Item
  - Islam, Prioty, Helen Tang, Haesu Jin, Felicia Cao, Lauren M. Bohannon, Yi Ren, Nelson J. Chao, et al. “Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation.” Transplant Cell Ther 27, no. 9 (September 2021): 784.e1-784.e7. https://doi.org/10.1016/j.jtct.2021.06.012.
    Full Text Link to Item
  - Bohannon, Lauren, Helen Tang, Kristin Page, Yi Ren, Sin-Ho Jung, Alexandra Artica, Anne Britt, et al. “Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.” Transplant Cell Ther 27, no. 8 (August 2021): 669.e1-669.e8. https://doi.org/10.1016/j.jtct.2021.05.002.
    Full Text Open Access Copy Link to Item
  - Mo, Clifton C., Sundar Jagannath, Ajai Chari, Ajay K. Nooka, Sagar Lonial, David Siegel, Noa Biran, Cristina Gasparetto, Nizar J. Bahlis, and Paul Richardson. “Selinexor for the treatment of patients with previously treated multiple myeloma.” Expert Rev Hematol 14, no. 8 (August 2021): 697–706. https://doi.org/10.1080/17474086.2021.1923473.
    Full Text Link to Item
  - Lee, Hans C., Sikander Ailawadhi, Cristina J. Gasparetto, Sundar Jagannath, Robert M. Rifkin, Brian G. M. Durie, Mohit Narang, et al. “Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry.” Blood Cancer J 11, no. 7 (July 23, 2021): 134. https://doi.org/10.1038/s41408-021-00524-1.
    Full Text Link to Item
  - Pabon, Cindy M., Zhiguo Li, Therese Hennig, Carlos de Castro, Jadee L. Neff, Mitchell E. Horwitz, Thomas W. LeBlanc, et al. “Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.” Blood Cancer J 11, no. 5 (May 16, 2021): 92. https://doi.org/10.1038/s41408-021-00481-9.
    Full Text Open Access Copy Link to Item
  - Mikhael, Joseph, Karim Belhadj-Merzoug, Cyrille Hulin, Laure Vincent, Philippe Moreau, Cristina Gasparetto, Ludek Pour, et al. “A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.” Blood Cancer J 11, no. 5 (May 12, 2021): 89. https://doi.org/10.1038/s41408-021-00478-4.
    Full Text Link to Item
  - Abonour, Rafat, Robert M. Rifkin, Cristina Gasparetto, Kathleen Toomey, Brian G. M. Durie, James W. Hardin, Howard R. Terebelo, et al. “Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry.” Br J Haematol 193, no. 1 (April 2021): 93–100. https://doi.org/10.1111/bjh.17131.
    Full Text Link to Item
  - Kaufman, Jonathan L., Cristina Gasparetto, Fredrik H. Schjesvold, Philippe Moreau, Cyrille Touzeau, Thierry Facon, Lawrence H. Boise, et al. “Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.” Am J Hematol 96, no. 4 (April 1, 2021): 418–27. https://doi.org/10.1002/ajh.26083.
    Full Text Link to Item
  - Dimopoulos, Meletios, Sara Bringhen, Pekka Anttila, Marcelo Capra, Michele Cavo, Craig Cole, Cristina Gasparetto, et al. “Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.” Blood 137, no. 9 (March 4, 2021): 1154–65. https://doi.org/10.1182/blood.2020008209.
    Full Text Link to Item
  - Giri, Vinay K., Kristin G. Kegerreis, Yi Ren, Lauren M. Bohannon, Erica Lobaugh-Jin, Julia A. Messina, Anita Matthews, et al. “Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation.” Transplant Cell Ther 27, no. 3 (March 2021): 262.e1-262.e11. https://doi.org/10.1016/j.jtct.2021.01.004.
    Full Text Link to Item
  - Racioppi, Alessandro, Tara Dalton, Sendhilnathan Ramalingam, Kristi Romero, Yi Ren, Lauren Bohannon, Consuelo Arellano, et al. “Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients.” Transplant Cell Ther 27, no. 2 (February 2021): 181.e1-181.e9. https://doi.org/10.1016/j.jtct.2020.10.017.
    Full Text Link to Item
  - Maung, Ko K., Benny J. Chen, Ian Barak, Zhiguo Li, David A. Rizzieri, Cristina Gasparetto, Keith M. Sullivan, et al. “Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.” Bone Marrow Transplant 56, no. 1 (January 2021): 137–43. https://doi.org/10.1038/s41409-020-0991-5.
    Full Text Link to Item
  - Ramalingam, Sendhilnathan, Sharareh Siamakpour-Reihani, Lauren Bohannan, Yi Ren, Alexander Sibley, Jeff Sheng, Li Ma, et al. “A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.” Plos One 16, no. 6 (2021): e0252995. https://doi.org/10.1371/journal.pone.0252995.
    Full Text Link to Item
  - Kumar, Shaji K., Simon J. Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, et al. “Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.” Lancet Oncol 21, no. 12 (December 2020): 1630–42. https://doi.org/10.1016/S1470-2045(20)30525-8.
    Full Text Link to Item
  - Mikhael, Joseph, Joshua Richter, Ravi Vij, Craig Cole, Jeffrey Zonder, Jonathan L. Kaufman, William Bensinger, et al. “A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.” Leukemia 34, no. 12 (December 2020): 3298–3309. https://doi.org/10.1038/s41375-020-0857-2.
    Full Text Link to Item
  - Smith, Patrick, Jillian C. Thompson, Elena Perea, Brian Wasserman, Lauren Bohannon, Alessandro Racioppi, Taewoong Choi, et al. “Clinical and Neuroimaging Correlates of Post-Transplant Delirium.” Biol Blood Marrow Transplant 26, no. 12 (December 2020): 2323–28. https://doi.org/10.1016/j.bbmt.2020.09.016.
    Full Text Link to Item
  - Ailawadhi, Sikander, Sundar Jagannath, Hans C. Lee, Mohit Narang, Robert M. Rifkin, Howard R. Terebelo, Brian G. M. Durie, et al. “Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis.” Cancer 126, no. 19 (October 1, 2020): 4332–40. https://doi.org/10.1002/cncr.33089.
    Full Text Link to Item
  - Gavriatopoulou, Maria, Ajai Chari, Christine Chen, Nizar Bahlis, Dan T. Vogl, Andrzej Jakubowiak, David Dingli, et al. “Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.” Leukemia 34, no. 9 (September 2020): 2430–40. https://doi.org/10.1038/s41375-020-0756-6.
    Full Text Link to Item
  - Chari, Ajai, Robert F. Cornell, Cristina Gasparetto, Chatchada Karanes, Jeffrey V. Matous, Ruben Niesvizky, Matthew Lunning, et al. “Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.” Hematol Oncol 38, no. 3 (August 2020): 353–62. https://doi.org/10.1002/hon.2723.
    Full Text Link to Item
  - Jagannath, Sundar, Robert M. Rifkin, Cristina J. Gasparetto, Kathleen Toomey, Brian G. M. Durie, James W. Hardin, Howard R. Terebelo, et al. “Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry.” Clin Lymphoma Myeloma Leuk 20, no. 5 (May 2020): 272–76. https://doi.org/10.1016/j.clml.2019.10.002.
    Full Text Link to Item
  - Ailawadhi, Sikander, Sundar Jagannath, Mohit Narang, Robert M. Rifkin, Howard R. Terebelo, Kathleen Toomey, Brian G. M. Durie, et al. “Connect MM Registry as a national reference for United States multiple myeloma patients.” Cancer Med 9, no. 1 (January 2020): 35–42. https://doi.org/10.1002/cam4.2656.
    Full Text Link to Item
  - Maung, Ko, Sendhilnathan Ramalingam, Mohammad Chaudhry, Yi Ren, Sin-Ho Jung, Kristi Romero, Kelly Corbet, et al. “Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality.” Plos One 15, no. 9 (2020): e0238824. https://doi.org/10.1371/journal.pone.0238824.
    Full Text Link to Item
  - Terebelo, Howard R., Rafat Abonour, Cristina J. Gasparetto, Kathleen Toomey, Brian G. M. Durie, James W. Hardin, Sundar Jagannath, et al. “Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry.” Br J Haematol 187, no. 5 (December 2019): 602–14. https://doi.org/10.1111/bjh.16139.
    Full Text Link to Item
  - Gopalakrishnan, Sathish, Anita D’Souza, Emma Scott, Raphael Fraser, Omar Davila, Nina Shah, Robert Peter Gale, et al. “Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.” Biol Blood Marrow Transplant 25, no. 4 (April 2019): 683–88. https://doi.org/10.1016/j.bbmt.2018.12.141.
    Full Text Link to Item
  - Stadtmauer, Edward A., Marcelo C. Pasquini, Beth Blackwell, Parameswaran Hari, Asad Bashey, Steven Devine, Yvonne Efebera, et al. “Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.” J Clin Oncol 37, no. 7 (March 1, 2019): 589–97. https://doi.org/10.1200/JCO.18.00685.
    Full Text Link to Item
  - Zheng, Jing, Yonggang Sha, Logan Roof, Oded Foreman, John Lazarchick, Jagadish Kummetha Venkta, Cleopatra Kozlowski, et al. “Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.” Cancer Lett 440–441 (January 2019): 1–10. https://doi.org/10.1016/j.canlet.2018.10.003.
    Full Text Link to Item
  - Bahlis, Nizar J., Heather Sutherland, Darrell White, Michael Sebag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, et al. “Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.” Blood 132, no. 24 (December 13, 2018): 2546–54. https://doi.org/10.1182/blood-2018-06-858852.
    Full Text Link to Item
  - Abonour, Rafat, Lynne Wagner, Brian G. M. Durie, Sundar Jagannath, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, et al. “Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.” Ann Hematol 97, no. 12 (December 2018): 2425–36. https://doi.org/10.1007/s00277-018-3446-y.
    Full Text Link to Item
  - Chari, Ajai, Sarah Larson, Beata Holkova, Robert F. Cornell, Cristina Gasparetto, Chatchada Karanes, Jeffrey V. Matous, et al. “Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.” Leuk Lymphoma 59, no. 11 (November 2018): 2588–94. https://doi.org/10.1080/10428194.2018.1443337.
    Full Text Link to Item
  - Sivaraj, Dharshan, Michael M. Green, Yubin Kang, Gwynn D. Long, David A. Rizzieri, Zhiguo Li, Anderson H. Garrett, Jackie L. McIntyre, Nelson J. Chao, and Cristina Gasparetto. “Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.” Blood Cancer J 8, no. 8 (July 31, 2018): 71. https://doi.org/10.1038/s41408-018-0104-5.
    Full Text Link to Item
  - Jagannath, Sundar, Rafat Abonour, Brian G. M. Durie, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, Kathleen Toomey, et al. “Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.” Blood Adv 2, no. 13 (July 10, 2018): 1608–15. https://doi.org/10.1182/bloodadvances.2018017186.
    Full Text Link to Item
  - Jagannath, Sundar, Rafat Abonour, Brian G. M. Durie, Cristina Gasparetto, James W. Hardin, Mohit Narang, Howard R. Terebelo, et al. “Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016).” Clin Lymphoma Myeloma Leuk 18, no. 7 (July 2018): 480-485.e3. https://doi.org/10.1016/j.clml.2018.04.007.
    Full Text Link to Item
  - Rifkin, Robert M., Sundar Jagannath, Brian G. M. Durie, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, Kathleen Toomey, et al. “Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.” Clin Ther 40, no. 7 (July 2018): 1193-1202.e1. https://doi.org/10.1016/j.clinthera.2018.05.017.
    Full Text Link to Item
  - Sundaramoorthy, Pasupathi, Cristina Gasparetto, and Yubin Kang. “The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.” Cancer Med 7, no. 7 (July 2018): 3257–68. https://doi.org/10.1002/cam4.1543.
    Full Text Link to Item
  - Kumar, S. K., A. Dispenzieri, R. Fraser, F. Mingwei, G. Akpek, R. Cornell, M. Kharfan-Dabaja, et al. “Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.” Leukemia 32, no. 4 (April 2018): 986–95. https://doi.org/10.1038/leu.2017.331.
    Full Text Link to Item
  - Htut, Myo, Anita D’Souza, Amrita Krishnan, Benedetto Bruno, Mei-Jie Zhang, Mingwei Fei, Miguel Angel Diaz, et al. “Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.” Biol Blood Marrow Transplant 24, no. 3 (March 2018): 478–85. https://doi.org/10.1016/j.bbmt.2017.10.024.
    Full Text Link to Item
  - Zheng, Zhihong, Shengjun Fan, Jing Zheng, Wei Huang, Cristina Gasparetto, Nelson J. Chao, Jianda Hu, and Yubin Kang. “Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.” J Hematol Oncol 11, no. 1 (February 27, 2018): 29. https://doi.org/10.1186/s13045-018-0575-7.
    Full Text Link to Item
  - Sivaraj, D., W. Bacon, G. D. Long, D. A. Rizzieri, M. E. Horwitz, K. M. Sullivan, Y. Kang, Z. Li, N. J. Chao, and C. Gasparetto. “High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.” Bone Marrow Transplant 53, no. 1 (January 2018): 34–38. https://doi.org/10.1038/bmt.2017.208.
    Full Text Link to Item
  - Huang, Li-Wen, Wendi Bacon, Constance Cirrincione, Bercedis Peterson, Gwynn Long, David Rizzieri, Keith M. Sullivan, et al. “Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.” Hematol Oncol 35, no. 4 (December 2017): 752–59. https://doi.org/10.1002/hon.2379.
    Full Text Link to Item
  - Kumar, Shaji, Jonathan L. Kaufman, Cristina Gasparetto, Joseph Mikhael, Ravi Vij, Brigitte Pegourie, Lofti Benboubker, et al. “Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.” Blood 130, no. 22 (November 30, 2017): 2401–9. https://doi.org/10.1182/blood-2017-06-788786.
    Full Text Link to Item
  - Terebelo, Howard, Shankar Srinivasan, Mohit Narang, Rafat Abonour, Cristina Gasparetto, Kathleen Toomey, James W. Hardin, et al. “Recognition of early mortality in multiple myeloma by a prediction matrix.” Am J Hematol 92, no. 9 (September 2017): 915–23. https://doi.org/10.1002/ajh.24796.
    Full Text Link to Item
  - Shah, Jatin J., Rafat Abonour, Christina Gasparetto, James W. Hardin, Kathleen Toomey, Mohit Narang, Shankar Srinivasan, et al. “Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes.” Clin Lymphoma Myeloma Leuk 17, no. 9 (September 2017): 575-583.e2. https://doi.org/10.1016/j.clml.2017.06.013.
    Full Text Link to Item
  - Vogl, Dan T., Thomas G. Martin, Ravi Vij, Parameswaran Hari, Joseph R. Mikhael, David Siegel, Ka Lung Wu, Michel Delforge, and Cristina Gasparetto. “Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.” Leuk Lymphoma 58, no. 8 (August 2017): 1872–79. https://doi.org/10.1080/10428194.2016.1263842.
    Full Text Link to Item
  - Anand, Sarah, Samantha Thomas, Terry Hyslop, Janet Adcock, Kelly Corbet, Cristina Gasparetto, Richard Lopez, et al. “Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization.” Biol Blood Marrow Transplant 23, no. 7 (July 2017): 1151–57. https://doi.org/10.1016/j.bbmt.2017.04.001.
    Full Text Link to Item
  - Voorhees, Peter M., Cristina Gasparetto, Dominic T. Moore, Diane Winans, Robert Z. Orlowski, and David D. Hurd. “Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.” Clin Lymphoma Myeloma Leuk 17, no. 7 (July 2017): 424–32. https://doi.org/10.1016/j.clml.2017.05.007.
    Full Text Link to Item
  - Tuchman, Sascha A., Joseph O. Moore, Carlos D. DeCastro, Zhiguo Li, Emily Sellars, Yubin Kang, Gwynn Long, and Cristina G. Gasparetto. “Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.” J Geriatr Oncol 8, no. 3 (May 2017): 165–69. https://doi.org/10.1016/j.jgo.2017.02.004.
    Full Text Link to Item
  - Sivaraj, Dharshan, Michael M. Green, and Cristina Gasparetto. “Panobinostat for the management of multiple myeloma.” Future Oncol 13, no. 6 (March 2017): 477–88. https://doi.org/10.2217/fon-2016-0329.
    Full Text Link to Item
  - Kumar, Shaji K., Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J Sybil Biermann, Jason C. Chandler, Caitlin Costello, et al. “Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 15, no. 2 (February 2017): 230–69. https://doi.org/10.6004/jnccn.2017.0023.
    Full Text Link to Item
  - Sivaraj, Dharshan, Michael M. Green, Zhiguo Li, Anthony D. Sung, Stefanie Sarantopoulos, Yubin Kang, Gwynn D. Long, et al. “Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.” Biol Blood Marrow Transplant 23, no. 2 (February 2017): 262–68. https://doi.org/10.1016/j.bbmt.2016.11.010.
    Full Text Link to Item
  - LeBlanc, T. W., A. Howson, W. Turell, P. Sheldon, S. C. Locke, S. A. Tuchman, C. Gasparetto, S. Kaura, Z. M. Khan, and A. P. Abernethy. “Risk stratification, treatment selection, and transplant eligibility in multiple myeloma: a qualitative study of the perspectives and self-reported practices of oncologists.” Curr Oncol 23, no. 6 (December 2016): e598–604. https://doi.org/10.3747/co.23.3298.
    Full Text Link to Item
  - Sung, Anthony D., Julia A. M. Sung, Samantha Thomas, Terry Hyslop, Cristina Gasparetto, Gwynn Long, David Rizzieri, et al. “Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial.” Clin Infect Dis 63, no. 8 (October 15, 2016): 999–1006. https://doi.org/10.1093/cid/ciw451.
    Full Text Link to Item
  - Scott, Emma C., Parameswaran Hari, Manish Sharma, Jennifer Le-Rademacher, Jiaxing Huang, Dan Vogl, Muneer Abidi, et al. “Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.” Biol Blood Marrow Transplant 22, no. 10 (October 2016): 1893–99. https://doi.org/10.1016/j.bbmt.2016.07.007.
    Full Text Link to Item
  - Rifkin, Robert M., Rafat Abonour, Jatin J. Shah, Jayesh Mehta, Mohit Narang, Howard Terebelo, Cristina Gasparetto, et al. “Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.” Leuk Lymphoma 57, no. 9 (September 2016): 2228–31. https://doi.org/10.3109/10428194.2015.1132419.
    Full Text Link to Item
  - Green, Michael M. B., Nelson Chao, Saurabh Chhabra, Kelly Corbet, Cristina Gasparetto, Ari Horwitz, Zhiguo Li, et al. “Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.” J Hematol Oncol 9, no. 1 (August 17, 2016): 71. https://doi.org/10.1186/s13045-016-0301-2.
    Full Text Open Access Copy Link to Item
  - Sivaraj, Dharshan, Michael Martin Green, Abdullah Mucahit Ciftci, Mohammad Faizan Zahid, Angela Anne Johns, Maureen Ross, and Cristina Gasparetto. “Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach.” Clin Lymphoma Myeloma Leuk 16, no. 6 (June 2016): e95–100. https://doi.org/10.1016/j.clml.2016.03.002.
    Full Text Link to Item
  - Dimopoulos, Meletios A., Pieter Sonneveld, Nelson Leung, Giampaolo Merlini, Heinz Ludwig, Efstathios Kastritis, Hartmut Goldschmidt, et al. “International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.” J Clin Oncol 34, no. 13 (May 1, 2016): 1544–57. https://doi.org/10.1200/JCO.2015.65.0044.
    Full Text Link to Item
  - Anderson, Kenneth C., Melissa Alsina, Djordje Atanackovic, J Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, et al. “NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.” J Natl Compr Canc Netw 14, no. 4 (April 2016): 389–400. https://doi.org/10.6004/jnccn.2016.0046.
    Full Text Link to Item
  - Baz, Rachid C., Jeffrey A. Zonder, Cristina Gasparetto, Frederic J. Reu, and Vincent Strout. “Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.” Oncol Ther 4, no. 2 (2016): 287–301. https://doi.org/10.1007/s40487-016-0034-y.
    Full Text Link to Item
  - Shah, Jatin J., Edward A. Stadtmauer, Rafat Abonour, Adam D. Cohen, William I. Bensinger, Cristina Gasparetto, Jonathan L. Kaufman, et al. “Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.” Blood 126, no. 20 (November 12, 2015): 2284–90. https://doi.org/10.1182/blood-2015-05-643320.
    Full Text Link to Item
  - Anderson, Kenneth C., Melissa Alsina, Djordje Atanackovic, J Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, et al. “Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 13, no. 11 (November 2015): 1398–1435. https://doi.org/10.6004/jnccn.2015.0167.
    Full Text Link to Item
  - Rifkin, Robert M., Rafat Abonour, Howard Terebelo, Jatin J. Shah, Cristina Gasparetto, James Hardin, Shankar Srinivasan, Rosanna Ricafort, Yasir Nagarwala, and Brian G. M. Durie. “Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics.” Clin Lymphoma Myeloma Leuk 15, no. 6 (June 2015): 368–76. https://doi.org/10.1016/j.clml.2014.12.002.
    Full Text Link to Item
  - Tuchman, Sascha A., Wendi A. Bacon, Li-Wen Huang, Gwynn Long, David Rizzieri, Mitchell Horwitz, John P. Chute, et al. “Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.” J Clin Apher 30, no. 3 (June 2015): 176–82. https://doi.org/10.1002/jca.21360.
    Full Text Link to Item
  - Tuchman, Sascha A., Amy Lane, Whitney E. Hornsby, Caroline Bishop, Samantha Thomas, James E. Herndon, Gwynn Long, Cristina Gasparetto, and Lee W. Jones. “Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study.” Clin Lymphoma Myeloma Leuk 15, no. 2 (February 2015): 103–9. https://doi.org/10.1016/j.clml.2014.09.002.
    Full Text Link to Item
  - Sharma, Manish, Mei-Jie Zhang, Xiaobo Zhong, Muneer H. Abidi, Görgün Akpek, Ulrike Bacher, Natalie S. Callander, et al. “Older patients with myeloma derive similar benefit from autologous transplantation.” Biol Blood Marrow Transplant 20, no. 11 (November 2014): 1796–1803. https://doi.org/10.1016/j.bbmt.2014.07.013.
    Full Text Link to Item
  - Horwitz, Mitchell E., Nelson J. Chao, David A. Rizzieri, Gwynn D. Long, Keith M. Sullivan, Cristina Gasparetto, John P. Chute, et al. “Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.” J Clin Invest 124, no. 7 (July 2014): 3121–28. https://doi.org/10.1172/JCI74556.
    Full Text Open Access Copy Link to Item
  - Saad, Ayman, Anuj Mahindra, Mei-Jie Zhang, Xiaobo Zhong, Luciano J. Costa, Angela Dispenzieri, William R. Drobyski, et al. “Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.” Biol Blood Marrow Transplant 20, no. 3 (March 2014): 402-408.e1. https://doi.org/10.1016/j.bbmt.2013.12.557.
    Full Text Link to Item
  - Kanda, Junya, Gwynn D. Long, Cristina Gasparetto, Mitchell E. Horwitz, Keith M. Sullivan, John P. Chute, Ashley Morris, et al. “Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.” Biol Blood Marrow Transplant 20, no. 2 (February 2014): 257–63. https://doi.org/10.1016/j.bbmt.2013.11.010.
    Full Text Link to Item
  - Saad, A., A. Mahindra, M. -. J. Zhang, X. Zhong, L. J. Costa, A. Dispenzieri, W. R. Drobyski, et al. “Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.” Biology of Blood and Marrow Transplantation 20, no. 3 (2014): 402–8.
  - Kanda, J., L. Kaynar, Y. Kanda, V. K. Prasad, S. H. Parikh, L. Lan, T. Shen, et al. “Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment.” Bone Marrow Transplant 48, no. 7 (July 2013): 926–31. https://doi.org/10.1038/bmt.2012.279.
    Full Text Open Access Copy Link to Item
  - Held, Lauren A., David Rizzieri, Gwynn D. Long, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Mitchell E. Horwitz, Nelson J. Chao, and Cristina Gasparetto. “A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.” Cancer Invest 31, no. 3 (March 2013): 172–76. https://doi.org/10.3109/07357907.2012.756109.
    Full Text Link to Item
  - Anderson, Kenneth C., Melissa Alsina, William Bensinger, J Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, et al. “Multiple myeloma, version 1.2013.” J Natl Compr Canc Netw 11, no. 1 (January 1, 2013): 11–17. https://doi.org/10.6004/jnccn.2013.0004.
    Full Text Link to Item
  - Spasojevic, Ivan, Ligia R. S. da Costa, Mitchell E. Horwitz, Gwynn D. Long, Keith M. Sullivan, John P. Chute, Cristina Gasparetto, Ashley Morris, Nelson J. Chao, and David A. Rizzieri. “Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.” Cancer Invest 30, no. 9 (November 2012): 679–82. https://doi.org/10.3109/07357907.2012.726386.
    Full Text Link to Item
  - Kanda, Junya, Lun-Wei Chiou, Paul Szabolcs, Gregory D. Sempowski, David A. Rizzieri, Gwynn D. Long, Keith M. Sullivan, et al. “Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation.” Biol Blood Marrow Transplant 18, no. 11 (November 2012): 1664-1676.e1. https://doi.org/10.1016/j.bbmt.2012.06.005.
    Full Text Link to Item
  - Anderson, Kenneth C., Melissa Alsina, William Bensinger, J Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, et al. “Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.” J Natl Compr Canc Netw 10, no. 10 (October 1, 2012): 1211–19. https://doi.org/10.6004/jnccn.2012.0128.
    Full Text Link to Item
  - Horwitz, M. E., J. P. Chute, C. Gasparetto, G. D. Long, C. McDonald, A. Morris, D. A. Rizzieri, K. M. Sullivan, and N. J. Chao. “Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.” Bone Marrow Transplant 47, no. 8 (August 2012): 1051–55. https://doi.org/10.1038/bmt.2011.217.
    Full Text Link to Item
  - Chen, D. -. F., V. K. Prasad, G. Broadwater, N. L. Reinsmoen, A. DeOliveira, A. Clark, K. M. Sullivan, et al. “Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.” Bone Marrow Transplant 47, no. 6 (June 2012): 817–23. https://doi.org/10.1038/bmt.2011.181.
    Full Text Link to Item
  - Kanda, J., M. E. Horwitz, G. D. Long, C. Gasparetto, K. M. Sullivan, J. P. Chute, A. Morris, et al. “Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.” Bone Marrow Transplant 47, no. 5 (May 2012): 700–705. https://doi.org/10.1038/bmt.2011.158.
    Full Text Link to Item
  - Tuchman, S. A., N. J. Chao, and C. G. Gasparetto. “Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.” Adv Hematol 2012 (2012): 712613. https://doi.org/10.1155/2012/712613.
    Full Text Link to Item
  - Anderson, Kenneth C., Melissa Alsina, William Bensinger, J Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, et al. “Multiple myeloma.” J Natl Compr Canc Netw 9, no. 10 (October 2011): 1146–83. https://doi.org/10.6004/jnccn.2011.0095.
    Full Text Link to Item
  - Kanda, Junya, David A. Rizzieri, Cristina Gasparetto, Gwynn D. Long, John P. Chute, Keith M. Sullivan, Ashley Morris, et al. “Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.” Biol Blood Marrow Transplant 17, no. 6 (June 2011): 867–74. https://doi.org/10.1016/j.bbmt.2010.09.009.
    Full Text Link to Item
  - Lokhorst, H., H. Einsele, D. Vesole, B. Bruno, J. San Miguel, J. A. Perez-Simon, N. M. Kröger, et al. “Reply to A. Gratwohl.” Journal of Clinical Oncology 29, no. 16 (June 1, 2011). https://doi.org/10.1200/JCO.2011.34.6718.
    Full Text
  - Craciunescu, Oana I., Beverly A. Steffey, Chris R. Kelsey, Nicole A. Larrier, Cathy J. Paarz-Largay, Robert G. Prosnitz, Nelson Chao, et al. “Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial.” Int J Radiat Oncol Biol Phys 79, no. 4 (March 15, 2011): 1248–55. https://doi.org/10.1016/j.ijrobp.2010.05.036.
    Full Text Link to Item
  - Herold, Christina I., Cristina Gasparetto, and Gowthami M. Arepally. “Lenalidomide-Associated ITP.” Case Rep Hematol 2011 (2011): 638020. https://doi.org/10.1155/2011/638020.
    Full Text Link to Item
  - Rizzieri, David A., Christopher Crout, Robert Storms, Jared Golob, Gwynn D. Long, Cristina Gasparetto, Keith M. Sullivan, et al. “Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.” Cancer Invest 29, no. 1 (January 2011): 56–61. https://doi.org/10.3109/07357907.2010.535055.
    Full Text Link to Item
  - Lokhorst, Henk, Hermann Einsele, David Vesole, Benedetto Bruno, Jesus San Miguel, Jose A. Pérez-Simon, Nicolaus Kröger, et al. “International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.” J Clin Oncol 28, no. 29 (October 10, 2010): 4521–30. https://doi.org/10.1200/JCO.2010.29.7929.
    Full Text Link to Item
  - Rizzieri, David A., Robert Storms, Dong-Feng Chen, Gwynn Long, Yiping Yang, Daniel A. Nikcevich, Cristina Gasparetto, et al. “Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.” Biol Blood Marrow Transplant 16, no. 8 (August 2010): 1107–14. https://doi.org/10.1016/j.bbmt.2010.02.018.
    Full Text Link to Item
  - Crout, Christopher A., Liang-Piu Koh, Jon P. Gockerman, Joseph O. Moore, Carlos Decastro, Gwynn D. Long, Louis Diehl, et al. “Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.” Cancer Invest 28, no. 6 (July 2010): 654–60. https://doi.org/10.3109/07357901003631015.
    Full Text Link to Item
  - Kumar, S. K., I. Flinn, S. J. Noga, P. Hari, R. Rifkin, N. Callander, M. Bhandari, et al. “Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.” Leukemia 24, no. 7 (July 2010): 1350–56. https://doi.org/10.1038/leu.2010.116.
    Full Text Link to Item
  - Gasparetto, Cristina, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Gwynn D. Long, Mitchell E. Horwitz, et al. “"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.” Biol Blood Marrow Transplant 16, no. 1 (January 2010): 70–77. https://doi.org/10.1016/j.bbmt.2009.08.017.
    Full Text Link to Item
  - Anderson, Kenneth C., Melissa Alsina, William Bensinger, J Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, et al. “NCCN clinical practice guidelines in oncology: multiple myeloma.” J Natl Compr Canc Netw 7, no. 9 (October 2009): 908–42. https://doi.org/10.6004/jnccn.2009.0061.
    Full Text Link to Item
  - Anguiano, Ariel, Sascha A. Tuchman, Chaitanya Acharya, Kelly Salter, Cristina Gasparetto, Fenghuang Zhan, Madhav Dhodapkar, et al. “Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.” J Clin Oncol 27, no. 25 (September 1, 2009): 4197–4203. https://doi.org/10.1200/JCO.2008.19.1916.
    Full Text Link to Item
  - Rizzieri, D. A., P. Dev, G. D. Long, C. Gasparetto, K. M. Sullivan, Ml Horwitz, J. Chute, and N. J. Chao. “Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.” Bone Marrow Transplant 43, no. 4 (February 2009): 327–33. https://doi.org/10.1038/bmt.2008.321.
    Full Text Link to Item
  - Palmer, Jeanne, Timothy Goggins, Gloria Broadwater, Nelson J. Chao, John Chute, R. E. Coleman, Keith M. Sullivan, et al. “Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma.” Blood 112, no. 11 (November 16, 2008): 760–760.
    Link to Item
  - Rizzieri, Davd A., Robert Storms, Daniel Nikcevich, Bercedis Peterson, Debashish Misra, Christine Apple, Megan Baker, et al. “Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation.” Blood 112, no. 11 (November 16, 2008): 133–34.
    Link to Item
  - Horwitz, Mitchell E., Ashley Morris, Cristina Gasparetto, Keith Sullivan, Gwynn Long, John Chute, David Rizzieri, Jackie McPherson, and Nelson Chao. “Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.” Biol Blood Marrow Transplant 14, no. 5 (May 2008): 591–94. https://doi.org/10.1016/j.bbmt.2008.02.016.
    Full Text Link to Item
  - Byrne, B. J., M. Horwitz, G. D. Long, C. Gasparetto, K. M. Sullivan, J. Chute, N. J. Chao, and D. A. Rizzieri. “Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection.” Bone Marrow Transplant 41, no. 1 (January 2008): 39–43. https://doi.org/10.1038/sj.bmt.1705882.
    Full Text Link to Item
  - Horwitz, Mitchell E., Ivan Spasojevic, Ashley Morris, Marilyn Telen, James Essell, Cristina Gasparetto, Keith Sullivan, et al. “Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics.” Biol Blood Marrow Transplant 13, no. 12 (December 2007): 1422–26. https://doi.org/10.1016/j.bbmt.2007.08.050.
    Full Text Link to Item
  - Rizzieri, David A., Liang Piu Koh, Gwynn D. Long, Cristina Gasparetto, Keith M. Sullivan, Mitchell Horwitz, John Chute, et al. “Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.” J Clin Oncol 25, no. 6 (February 20, 2007): 690–97. https://doi.org/10.1200/JCO.2006.07.0953.
    Full Text Link to Item
  - Lagoo, Anand S., Jerald Z. Gong, Timothy T. Stenzel, Barbara K. Goodman, Patrick J. Buckley, Nelson J. Chao, Cristina Gasparetto, Gwynn D. Long, and David A. Rizzieri. “Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment.” Arch Pathol Lab Med 130, no. 10 (October 2006): 1479–88. https://doi.org/10.5858/2006-130-1479-MEOSBM.
    Full Text Link to Item
  - Chao, Nelson. “Hematopoietic stem cell transplantation.” Curr Opin Hematol 11, no. 6 (November 2004): 373–74. https://doi.org/10.1097/01.moh.0000144500.82861.c0.
    Full Text Link to Item
  - Nieto, Yago, James J. Vredenburgh, Elizabeth J. Shpall, Scott I. Bearman, Peter A. McSweeney, Nelson Chao, David Rizzieri, et al. “Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer.” Clin Cancer Res 10, no. 21 (November 1, 2004): 7136–43. https://doi.org/10.1158/1078-0432.CCR-04-0891.
    Full Text Link to Item
  - Chao, Nelson J., Liang-Piu Koh, Gwynn D. Long, Cristina Gasparetto, Mitchell Horwitz, Ashley Morris, Martha Lassiter, Keith M. Sullivan, and David A. Rizzieri. “Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens.” Biol Blood Marrow Transplant 10, no. 8 (August 2004): 569–75. https://doi.org/10.1016/j.bbmt.2004.05.001.
    Full Text Link to Item
  - Rizzieri, David A., Gamal Akabani, Michael R. Zalutsky, R Edward Coleman, Scott D. Metzler, James E. Bowsher, Bonnie Toaso, et al. “Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.” Blood 104, no. 3 (August 1, 2004): 642–48. https://doi.org/10.1182/blood-2003-12-4264.
    Full Text Link to Item
  - Snyder, Matthew J., Timothy T. Stenzel, Patrick J. Buckley, Anand S. Lagoo, David A. Rizzieri, Cristina Gasparetto, James J. Vredenburgh, Nelson J. Chao, and Jerald Z. Gong. “Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation.” Am J Surg Pathol 28, no. 6 (June 2004): 794–800. https://doi.org/10.1097/01.pas.0000126052.88174.f.
    Full Text Link to Item
  - Rizzieri, David A., Gregory J. Sand, Dean McGaughey, Joseph O. Moore, Carlos DeCastro, Nelson J. Chao, James J. Vredenburgh, et al. “Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.” Cancer 100, no. 11 (June 1, 2004): 2408–14. https://doi.org/10.1002/cncr.20245.
    Full Text Link to Item
  - Gasparetto, Cristina. “Stem cell transplantation for multiple myeloma.” Cancer Control 11, no. 2 (2004): 119–29. https://doi.org/10.1177/107327480401100218.
    Full Text Link to Item
  - Long, Gwynn D., Mary Laughlin, Bella Madan, Joanne Kurtzberg, Cristina Gasparetto, Ashley Morris, David Rizzieri, et al. “Unrelated umbilical cord blood transplantation in adult patients.” Biol Blood Marrow Transplant 9, no. 12 (December 2003): 772–80. https://doi.org/10.1016/j.bbmt.2003.08.007.
    Full Text Link to Item
  - Rizzieri, David A., Jeffrey T. Talbot, Gwynn D. Long, James J. Vredenburgh, Christina Gasparetto, Clayton S. Smith, Michael O. Colvin, et al. “4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia.” Biol Blood Marrow Transplant 9, no. 3 (March 2003): 183–88. https://doi.org/10.1053/bbmt.2003.50011.
    Full Text Link to Item
  - Rizzieri, David A., Valerie K. Ibom, Joseph O. Moore, Carlos M. DeCastro, Gary L. Rosner, David J. Adams, Traci Foster, et al. “Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.” Clin Cancer Res 9, no. 2 (February 2003): 663–68.
    Link to Item
  - McCune, Steven L., Jon P. Gockerman, Joseph O. Moore, Carlos M. Decastro, Adam J. Bass, Nelson J. Chao, Gwynn D. Long, et al. “Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.” Leuk Lymphoma 43, no. 5 (May 2002): 1007–11. https://doi.org/10.1080/10428190290021597.
    Full Text Link to Item
  - Gasparetto, Cristina, Maura Gasparetto, Michael Morse, Barbara Rooney, James J. Vredenburgh, Gwynn D. Long, David A. Rizzieri, Jennifer Loftis, Nelson J. Chao, and Clay Smith. “Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF.” Cytokine 18, no. 1 (April 7, 2002): 8–19. https://doi.org/10.1006/cyto.2002.1009.
    Full Text Link to Item
  - Chao, Nelson J., Cong X. Liu, Barbara Rooney, Benny J. Chen, Gwynn D. Long, James J. Vredenburgh, Ashley Morris, Cristina Gasparetto, and David A. Rizzieri. “Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells.” Biol Blood Marrow Transplant 8, no. 5 (2002): 249–56. https://doi.org/10.1053/bbmt.2002.v8.pm12064361.
    Full Text Link to Item
  - Rizzieri, D. A., G. D. Long, J. J. Vredenburgh, C. Gasparetto, A. Morris, T. T. Stenzel, P. Davis, and N. J. Chao. “Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen.” Blood 98, no. 12 (December 1, 2001): 3486–88. https://doi.org/10.1182/blood.v98.12.3486.
    Full Text Link to Item
  - Gasparetto, C., C. Smith, A. Gillio, A. M. Stoppa, M. A. Moore, and R. J. O’Reilly. “Enrichment of peripheral blood stem cells in a primate model following administration of a single dose of rh-IL-1 beta.” Bone Marrow Transplant 14, no. 5 (November 1994): 717–23.
    Link to Item
  - Dennig, D., J. Lacerda, Y. Yan, C. Gasparetto, and R. J. O’Reilly. “ICAM-1 (CD54) expression on B lymphocytes is associated with their costimulatory function and can be increased by coactivation with IL-1 and IL-7.” Cell Immunol 156, no. 2 (July 1994): 414–23. https://doi.org/10.1006/cimm.1994.1186.
    Full Text Link to Item
  - Gasparetto, C., C. Smith, M. Firpo, D. Dennig, T. Small, A. P. Gillio, R. Lichtenberg, R. J. O’Reilly, and M. A. Moore. “Dyshematopoiesis in combined immune deficiency with congenital neutropenia.” Am J Hematol 45, no. 1 (January 1994): 63–72. https://doi.org/10.1002/ajh.2830450110.
    Full Text Link to Item
  - Muench, M. O., C. Gasparetto, and M. A. Moore. “The in vitro growth of murine high proliferative potential-colony forming cells is not enhanced by growth in a low oxygen atmosphere.” Cytokine 4, no. 6 (November 1992): 488–94. https://doi.org/10.1016/1043-4666(92)90009-g.
    Full Text Link to Item
  - Crown, J., A. Jakubowski, N. Kemeny, M. Gordon, C. Gasparetto, G. Wong, C. Sheridan, G. Toner, B. Meisenberg, and J. Botet. “A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer.” Blood 78, no. 6 (September 15, 1991): 1420–27.
    Link to Item
  - Smith, C., C. Gasparetto, N. Collins, A. Gillio, M. O. Muench, R. J. O’Reilly, and M. A. Moore. “Purification and partial characterization of a human hematopoietic precursor population.” Blood 77, no. 10 (May 15, 1991): 2122–28.
    Link to Item
  - Lemoli, R. M., C. Gasparetto, D. A. Scheinberg, M. A. Moore, B. D. Clarkson, and S. C. Gulati. “Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.” Blood 77, no. 8 (April 15, 1991): 1829–36.
    Link to Item
  - Gillio, A. P., C. Gasparetto, J. Laver, M. Abboud, M. A. Bonilla, M. B. Garnick, and R. J. O’Reilly. “Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates.” J Clin Invest 85, no. 5 (May 1990): 1560–65. https://doi.org/10.1172/JCI114605.
    Full Text Link to Item
  - Laver, J., E. Duncan, M. Abboud, C. Gasparetto, I. Sahdev, D. Warren, J. Bussel, P. Auld, R. J. O’Reilly, and M. A. Moore. “High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates.” J Pediatr 116, no. 4 (April 1990): 627–32. https://doi.org/10.1016/s0022-3476(05)81617-8.
    Full Text Link to Item
  - O’Reilly, R. J., A. Gillio, and C. Gasparetto. “Effects of hematopoietic growth factors following myeloablation in a primate model.” Int J Cell Cloning 8 Suppl 1 (January 1990): 262–67. https://doi.org/10.1002/stem.5530080724.
    Full Text Link to Item
  - Gasparetto, C., J. Laver, M. Abboud, A. Gillio, C. Smith, R. J. O’Reilly, and M. A. Moore. “Effects of interleukin-1 on hematopoietic progenitors: evidence of stimulatory and inhibitory activities in a primate model.” Blood 74, no. 2 (August 1, 1989): 547–50.
    Link to Item
  - Laver, J., M. Abboud, C. Gasparetto, A. Gillio, C. Smith, R. J. O’Reilly, and M. A. Moore. “Effects of IL-1 on hematopoietic progenitors after myelosuppressive chemoradiotherapy.” Biotherapy 1, no. 4 (1989): 293–300. https://doi.org/10.1007/BF02171005.
    Full Text Link to Item
- Conference Papers
  - Smith, Patrick J., Meagan Lew, Yen Lowder, Kristi Romero, Jillian C. Thompson, Lauren Bohannon, Alyssa Pittman, et al. “Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation.” In Bone Marrow Transplant, 57:89–94, 2022. https://doi.org/10.1038/s41409-021-01470-z.
    Full Text Link to Item
  - Lin, Chenyu, Laura Morrison, Edwin Alyea, Taewoong Choi, Cristina Gasparetto, Gwynn Long, Richard Lopez, et al. “Allogeneic Stem Cell Transplantation with Omidubicel: Long-Term Follow-Up from a Single Center.” In Blood, 138:1827–1827. American Society of Hematology, 2021.
    Link to Item
  - Stadtmauer, Edward, Lionel Karlin, Katja Weisel, Moshe Etzion Gatt, Ankit Kansagra, Gregory Monohan, Andrew Yee, et al. “448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study.” In Journal for Immunotherapy of Cancer, 9:A476–A476. BMJ, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.448.
    Full Text
  - Bahlis, Nizar J., Noopur S. Raje, Caitlin Costello, Bhagirathbhai R. Dholaria, Melhem M. Solh, Moshe Y. Levy, Michael H. Tomasson, et al. “Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).” In Journal of Clinical Oncology, 39:8006–8006. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.8006.
    Full Text
  - Gasparetto, Cristina, Brea Lipe, Sascha Tuchman, Nizar J. Bahlis, Heather J. Sutherland, Adriana C. Rossi, Suzanne Lentzsch, et al. “Selinexor containing regimens in patients with multiple myeloma (MM) previously treated with anti-CD38 monoclonal antibodies (αCD38 mAbs).” In Journal of Clinical Oncology, 39:e20020–e20020. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.e20020.
    Full Text
  - Gasparetto, Cristina, Gary J. Schiller, Sascha Tuchman, Natalie Scott Callander, Muhamed Baljevic, Suzanne Lentzsch, Adriana C. Rossi, et al. “Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.” In Journal of Clinical Oncology, 39:8038–8038. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.8038.
    Full Text
  - Nishihori, Taiga, Qaiser Bashir, Marcelo C. Pasquini, Michael Martens, Juan Wu, Melissa Alsina, Yvonne Adeduni Efebera, et al. “The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).” In Journal of Clinical Oncology, 39:7003–7003. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.7003.
    Full Text
  - White, Darrell, Christine Chen, Muhamed Baljevic, Sascha Tuchman, Nizar J. Bahlis, Gary J. Schiller, Brea Lipe, et al. “Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).” In Journal of Clinical Oncology, 39:8018–8018. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.8018.
    Full Text
  - Dholaria, Bhagirathbhai, Nizar Bahlis, Noopur Raje, Caitlin Costello, Melhem Solh, Moshe Levy, Michael Tomasson, et al. “MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM).” In Clinical Lymphoma Myeloma & Leukemia, 21:S17–S17, 2021.
    Link to Item
  - D’Souza, Anita, Ruta Brazauskas, Edward Stadtmauer, Marcelo Pasquini, Parameswaran Hari, Asad Bashey, Steven Devine, et al. “Trajectories of symptom and quality-of-life (QOL) recovery after autologous stem cell transplantation (ASCT) in multiple myeloma (MM): secondary analysis of BMT CTN 0702 trial.” In Quality of Life Research, 30:S32–33, 2021.
    Link to Item
  - Hultcrantz, Malin, Larry D Jr Anderson, Faiz Anwer, Cristina Gasparetto, Mehmet H. Kocoglu, Eben I. Lichtman, Clifton Mo, et al. “Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics.” In Clinical Lymphoma Myeloma & Leukemia, 21:S439–40, 2021.
    Link to Item
  - Levy, Moshe, Nizar Bahlis, Noopur Raje, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Michael Tomasson, et al. “MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM).” In Clinical Lymphoma Myeloma & Leukemia, 21:S439–S439, 2021.
    Link to Item
  - Wagner, Lynne, Rafat Abonour, Sikander Ailawadhi, Brian G. M. Durie, Cristina J. Gasparetto, James W. Hardin, Hans Lee, et al. “Health-related quality of life (HRQL) among real-world Ide-Cel-eligible patients (pts) with relapsed/refractory Multiple Myeloma (RRMM): results from the Connect (R) MM registry.” In Clinical Lymphoma Myeloma & Leukemia, 21:S109–S109, 2021.
    Link to Item
  - Pabon, Cindy M., Zhiguo Li, Therese Hennig, Carlos De Castro, Jadee Neff, Mitchell E. Horwitz, Thomas W. Leblanc, et al. “Morphologic Leukemia-Free State in Acute Myeloid Leukemia Is Sufficient for Successful Allogeneic Hematopoietic Stem Cell Transplant.” In Blood, 136:24–25. American Society of Hematology, 2020. https://doi.org/10.1182/blood-2020-133901.
    Full Text
  - Maung, Ko, Nelson Jen An Chao, Kelly Corbet, Ashley Morris Engemann, Cristina Gasparetto, Mitchell Horwitz, Yubin Kang, et al. “CLO20-049: Retrospective Study of Safety and Toxicity Profile Comparison for Propylene Glycol-Free Melphalan (Evomela®) and Generic Melphalan.” In Journal of the National Comprehensive Cancer Network, 18:CLO20-049. Harborside Press, LLC, 2020. https://doi.org/10.6004/jnccn.2019.7412.
    Full Text
  - Ramalingam, Sendhilnathan, Sharareh Siamakpour-Reihani, Lauren Bohannon, Yi Ren, Alexander Sibley, Andrew Nixon, Jing Lyu, et al. “Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT.” In Biology of Blood and Marrow Transplantation, 26:S48–49. ELSEVIER SCIENCE INC, 2020.
    Link to Item
  - Ailawadhi, Sikander, Hans Chulhee Lee, Jim Omel, Kathleen Toomey, James W. Hardin, Cristina Gasparetto, Sundar Jagannath, et al. “Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Gasparetto, Cristina, Brea Lipe, Sascha Tuchman, Natalie Scott Callander, Suzanne Lentzsch, Muhamed Baljevic, Adriana C. Rossi, et al. “Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Gasparetto, Cristina, Suzanne Lentzsch, Gary J. Schiller, Natalie Scott Callander, Sascha Tuchman, Nizar J. Bahlis, Darrell White, et al. “Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Kumar, Shaji, Simon J. Harrison, Michele Cavo, Javier de La Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, et al. “Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Bohannon, Lauren M., Kristin M. Page, Yi Ren, Sin-Ho Jung, Vinay K. Giri, Meagan V. Lew, Matthew Kelly, et al. “Decreased Mortality after the First Year of Allogeneic Hematopoietic Stem Cell Transplant in Recipients of Umbilical Cord Blood Vs. Matched Related or Matched Unrelated Donors.” In Blood, 134:4613–4613. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-126906.
    Full Text
  - Chen, Christine I., Nizar Bahlis, Cristina Gasparetto, Sascha A. Tuchman, Brea C. Lipe, Muhamed Baljevic, Rami Kotb, et al. “Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma.” In Blood, 134:141–141. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-122907.
    Full Text
  - Gasparetto, Cristina, Gary J. Schiller, Natalie Scott Callander, Suzanne Lentzsch, Sascha A. Tuchman, Nizar Bahlis, Darrell J. White, et al. “A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM).” In Blood, 134:3157–3157. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-122902.
    Full Text
  - Gasparetto, Cristina, Rakesh Popat, Shaji K. Kumar, Michele Cavo, Javier de la Rubia, Vania T. M. Hungria, Hans Salwender, et al. “Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone.” In Blood, 134:3177–3177. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-127387.
    Full Text
  - Giri, Vinay K., Kristin G. Kegerreis, Yi Ren, Lauren M. Bohannon, Erica Lobaugh-Jin, Julia A. Messina, Anita Matthews, et al. “Daily Chlorhexidine Gluconate Bathing Reduces the Rate of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Stem Cell Transplantation.” In Blood, 134:2210–2210. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-122272.
    Full Text
  - Harrison, Simon, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, Vania T. M. Hungria, Hans Salwender, et al. “T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study.” In Blood, 134:142–142. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-126094.
    Full Text
  - Kaufman, Jonathan L., Cristina Gasparetto, Fredrik H. Schjesvold, Philippe Moreau, Cyrille Touzeau, Thierry Facon, Lawrence H. Boise, et al. “Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma.” In Blood, 134:926–926. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-125871.
    Full Text
  - Lee, Hans C., Sikander Ailawadhi, Cristina Gasparetto, Sundar Jagannath, Robert M. Rifkin, Brian G. M. Durie, Mohit Narang, et al. “Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect® MM Registry.” In Blood, 134:3129–3129. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-126205.
    Full Text
  - Lew, Meagan V., Yi Ren, Yen P. Lowder, Kristi M. Romero, Jillian C. Thompson, Lauren M. Bohannon, Harvey Cohen, et al. “Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation.” In Blood, 134:1984–1984. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-127264.
    Full Text
  - Maung, Ko Ko Ko, Mohammad Chaudhry, Yi Ren, Sin-Ho Jung, Kristi M. Romero, Kelly Corbet, Nelson J. Chao, et al. “Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality.” In Blood, 134:5731–5731. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-121830.
    Full Text
  - McManigle, William C., Rachel A. DiCioccio, Sarah Anand, Zhiguo Li, Jonathan C. Poe, Krista R. Nichols, Amy N. Suthers, et al. “Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease.” In Blood, 134:4521–4521. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-130742.
    Full Text
  - Moreau, Philippe, Simon Harrison, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, Vania T. M. Hungria, et al. “Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.” In Blood, 134:1888–1888. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-126015.
    Full Text
  - Raje, Noopur S., Andrzej Jakubowiak, Cristina Gasparetto, Robert F. Cornell, Heike I. Krupka, Daniel Navarro, Alison J. Forgie, et al. “Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).” In Blood, 134:1869–1869. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-121805.
    Full Text
  - Richardson, Paul G., Myo Htut, Cristina Gasparetto, Jeffrey A. Zonder, Thomas G. Martin, Janice Chen, Christopher Brooks, et al. “Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.” In Blood, 134:3145–3145. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-130410.
    Full Text
  - Wagner, Lynne I., Kathleen Toomey, Sikander Ailawadhi, Sundar Jagannath, Cristina Gasparetto, Brian G. M. Durie, Mohit Narang, et al. “Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect® MM Registry.” In Blood, 134:1843–1843. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-126143.
    Full Text
  - White, Darrell J., Suzanne Lentzsch, Cristina Gasparetto, Nizar Bahlis, Christine I. Chen, Brea C. Lipe, Gary J. Schiller, et al. “Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma.” In Blood, 134:3165–3165. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-124370.
    Full Text
  - Ailawadhi, Sikander, Cristina J. Gasparetto, Sundar Jagannath, Robert Rifkin, Brian Durie, Mohit Narang, Howard Terebelo, et al. “Frequency of and Associations Amongst Baseline Cytogenetics in Patients With Newly Diagnosed Multiple Myeloma in the Connect® MM Registry.” In Clinical Lymphoma Myeloma and Leukemia, 19:e75–e75. Elsevier BV, 2019. https://doi.org/10.1016/j.clml.2019.09.119.
    Full Text
  - Gasparetto, Cristina J., Sundar Jagannath, Robert Rifkin, Brian Durie, Mohit Narang, Howard Terebelo, Kathleen Toomey, et al. “Effect of t(11;14) on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect® MM Registry.” In Clinical Lymphoma Myeloma and Leukemia, 19:e74–75. Elsevier BV, 2019. https://doi.org/10.1016/j.clml.2019.09.118.
    Full Text
  - Kumar, Shaji, Simon J. Harrison, Michele Cavo, Javier D. E. L. A. Rubia, Rakesh Popat, Cristina J. Gasparetto, Vania Hungria, et al. “A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.” In Clinical Lymphoma Myeloma and Leukemia, 19:e31–e31. Elsevier BV, 2019. https://doi.org/10.1016/j.clml.2019.09.046.
    Full Text
  - White, Darrell, Richard LeBlanc, Chritopher Venner, Nizar J. Bahlis, Suzanne Lentzsch, Cristina J. Gasparetto, Christine Chen, et al. “Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).” In Clinical Lymphoma Myeloma and Leukemia, 19:e55–e55. Elsevier BV, 2019. https://doi.org/10.1016/j.clml.2019.09.084.
    Full Text
  - Gasparetto, Cristina, Sundar Jagannath, Robert M. Rifkin, Brian G. Durie, Mohit Narang, Howard R. Terebelo, Kathleen Toomey, et al. “Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry.” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.
    Link to Item
  - Maung, Ko Ko, Benny J. Chen, David A. Rizzieri, Cristina Gasparetto, Keith Sullivan, Gwynn D. Long, Ashley Morris Engemann, et al. “Phase I, Dose Escalation Study of Naive T-Cell Depleted Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation.” In Biology of Blood and Marrow Transplantation, Vol. 25, 2019.
    Link to Item
  - Chen, Christine I., Heather J. Sutherland, Rami Kotb, Michael Sebag, Darrell J. White, William Bensinger, Cristina J. Gasparetto, et al. “Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma.” In Blood, 132:1993–1993. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-117349.
    Full Text
  - Dimopoulos, Meletios A., Sara Bringhen, Pekka Anttila, Marcelo Capra, Michele Cavo, Craig E. Cole, Cristina J. Gasparetto, et al. “Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.” In Blood, 132:155–155. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-155.
    Full Text
  - Gasparetto, Cristina J., Suzanne Lentzsch, Gary J. Schiller, William Bensinger, Nizar Bahlis, Heather J. Sutherland, Darrell J. White, et al. “Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd.” In Blood, 132:599–599. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-117201.
    Full Text
  - Jagannath, Sundar, Mohit Narang, Sikander Ailawadhi, Robert M. Rifkin, Howard R. Terebelo, Kathleen Toomey, Brian G. M. Durie, et al. “Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect® MM Registry.” In Blood, 132:3232–3232. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-110877.
    Full Text
  - Lesokhin, Alexander M., Noopur Raje, Cristina J. Gasparetto, Justine Walker, Heike I. Krupka, Tenshang Joh, Carrie T. Taylor, and Andrzej Jakubowiak. “A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma.” In Blood, 132:3229–3229. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-110427.
    Full Text
  - Abonour, R., R. M. Rifkin, C. Gasparetto, K. Toomey, B. G. M. Durie, J. W. Hardin, H. R. Terebelo, et al. “Impact of initial treatment (tx) on HRQoL and outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM) without intent for immediate transplant (SCT): Results from the Connect® MM registry.” In Ann Oncol, 29 Suppl 8:viii360, 2018. https://doi.org/10.1093/annonc/mdy286.003.
    Full Text Link to Item
  - Jagannath, Sundar, Robert M. Rifkin, Cristina Gasparetto, Kathleen Toomey, Brian G. Durie, James W. Hardin, Howard R. Terebelo, et al. “Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry.” In Journal of Clinical Oncology, 36:8041–8041. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.8041.
    Full Text
  - Anand, Sarah, Samantha Thomas, Kelly Corbet, Cristina Gasparetto, Gwynn D. Long, Richard Lopez, Ashley K. Morris, et al. “Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.” In Biol Blood Marrow Transplant, 23:1949–54, 2017. https://doi.org/10.1016/j.bbmt.2017.06.027.
    Full Text Link to Item
  - Sivaraj, Dharshan, Michael M. Green, Yubin Kang, David Rizzieri, Louis F. Diehl, Anne W. Beaven, Zhiguo Li, et al. “Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma.” In Journal of Clinical Oncology, 35:8008–8008. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.8008.
    Full Text
  - Abonour, Rafat, Brian Durie, Sundar Jagannath, Jatin Shah, Mohit Narang, Howard Terebelo, Cristina Gasparetto, et al. “Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry.” In Clinical Lymphoma Myeloma and Leukemia, 17:e89–90. Elsevier BV, 2017. https://doi.org/10.1016/j.clml.2017.03.160.
    Full Text
  - Krishnan, Amrita, Marcelo Pasquini, Beth Blackwell, Kristin Knust, Asad Bashey, Steven Devine, Yvonne Efebera, et al. “Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance.” In Clinical Lymphoma Myeloma and Leukemia, 17:e5–e5. Elsevier BV, 2017. https://doi.org/10.1016/j.clml.2017.03.009.
    Full Text
  - Kumar, Shaji, Jonathan L. Kaufman, Joseph Mikhael, Cristina Gasparetto, Ravi Vij, Brigitte Pegourie, Lofti Benboubker, et al. “Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma.” In Clinical Lymphoma Myeloma and Leukemia, 17:e27–e27. Elsevier BV, 2017. https://doi.org/10.1016/j.clml.2017.03.046.
    Full Text
  - Rifkin, Robert, Rafat Abonour, Brian Durie, Cristina Gasparetto, Sundar Jagannath, Mohit Narang, Jatin Shah, et al. “Treatment Patterns From 2009-2015 in Patients With Newly Diagnosed Multiple Myeloma in the United States: A Report From the Connect® MM Registry.” In Clinical Lymphoma Myeloma and Leukemia, 17:e20–21. Elsevier BV, 2017. https://doi.org/10.1016/j.clml.2017.03.035.
    Full Text
  - Dispenzieri, Angela, Shaji Kumar, Mei-Jie Zhang, Amrita Krishnan, Cristina Gasparetto, Yago Nieto, Raphael Fraser, Jiaxing Huang, Parameswaran Hari, and Anita D’Souza. “Trends in Survival Outcomes Among Patients (pts) Relapsing Early after Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) (CIBMTR Study # MM14-03).” In Biology of Blood and Marrow Transplantation, 23:S65–66, 2017.
    Link to Item
  - Abonour, Rafat, Brian G. M. Durie, Sundar Jagannath, Jatin J. Shah, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, et al. “Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect® MM Disease Registry.” In Blood, 128:537–537. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.537.537.
    Full Text
  - Anand, Sarah, Samantha Thomas, Kelly Corbet, Cristina Gasparetto, Richard Lopez, Gwynn D. Long, Ashley K. Morris, et al. “Adult Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation, Fludarabine, and Thiotepa Conditioning.” In Blood, 128:3395–3395. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.3395.3395.
    Full Text
  - Cohen, Adam D., Heather Landau, Emma C. Scott, Michaela Liedtke, Jonathan L. Kaufman, Michael Rosenzweig, Cristina Gasparetto, et al. “Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis.” In Blood, 128:645–645. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.645.645.
    Full Text
  - Htut, Myo, Anita D’Souza, Benedetto Bruno, Mei-Jie Zhang, Mingwei Fei, Cristina Gasparetto, Yago Nieto, Amrita Krishnan, and Parmeswaran Hari. “Survival after Relapse Following Tandem Allogeneic Vs. Tandem Autologous Hematopoietic Cell Transplantation (HCT) for Myeloma (MM).” In Blood, 128:833–833. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.833.833.
    Full Text
  - Htut, Myo, Cristina Gasparetto, Jeffrey Zonder, Thomas G. Martin, Emma C. Scott, Janice Chen, Shay Shemesh, et al. “Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.” In Blood, 128:5696–5696. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.5696.5696.
    Full Text
  - Kumar, Shaji, Ravi Vij, Jonathan L. Kaufman, Joseph Mikhael, Thierry Facon, Brigitte Pegourie, Lofti Benboubker, et al. “Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study.” In Blood, 128:488–488. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.488.488.
    Full Text
  - Rifkin, Robert M., Rafat Abonour, Brian G. M. Durie, Cristina J. Gasparetto, Sundar Jagannath, Mohit Narang, Jatin J. Shah, et al. “Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect® MM Registry.” In Blood, 128:4489–4489. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.4489.4489.
    Full Text
  - Kumar, Shaji, Ravi Vij, Jonathan L. Kaufman, Joseph Mikhael, Thierry Facon, Brigitte Pegourie, Lotfi Benboubker, et al. “Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.” In Journal of Clinical Oncology, Vol. 34. AMER SOC CLINICAL ONCOLOGY, 2016. https://doi.org/10.1200/JCO.2016.34.15_supp1.8032.
    Full Text Link to Item
  - Richter, Joshua Ryan, Thomas G. Martin, Ravi Vij, Craig Cole, Djordje Atanackovic, Jeffrey A. Zonder, Jonathan L. Kaufman, et al. “Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).” In Journal of Clinical Oncology, 34:8005–8005. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.8005.
    Full Text
  - Cornell, Robert F., Veronika Bachanova, Anita D’Souza, Kwang Woo Ahn, Jiaxing Huang, Amrita Krishnan, Cristina Gasparetto, Yago Nieto, Tomer M. Mark, and Parameswaran N. Hari. “Outcomes after Allogeneic Transplant for Lymphoplasmacytic Lymphoma/ Waldenstrom Macroglobulinemia (LPL/WM): A Center for International Blood and Marrow Transplant Research Analysis.” In Biology of Blood and Marrow Transplantation, 22:S219–S219. Elsevier BV, 2016. https://doi.org/10.1016/j.bbmt.2015.11.620.
    Full Text
  - Huang, Li-Wen, Wendi Bacon, Constance Cirrincione, Bercedis Peterson, Gwynn D. Long, David A. Rizzieri, Mitchell E. Horwitz, et al. “Efficacy of Autologous Stem Cell Transplantation in Older Multiple Myeloma Patients.” In Biology of Blood and Marrow Transplantation, 22:S223–S223. Elsevier BV, 2016. https://doi.org/10.1016/j.bbmt.2015.11.626.
    Full Text
  - Chari, Ajai, Saurabh Chhabra, Saad Usmani, Sarah Larson, Ruben Niesvizky, Jeffrey Matous, Cristina Gasparetto, et al. “Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Cornell, Robert Frank, Luciano J. Costa, Adetola A. Kassim, Racquel Inns-Shelton, Amrita Krishnan, Tomer Mark, Yago Nieto, et al. “Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM).” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Martin, Thomas, Joshua Richter, Ravi Vij, Craig Cole, Djordje Atanackovic, Jeffrey Zonder, Jonathan L. Kaufman, et al. “A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Shah, Jatin J., Rafat Abonour, Mohit Narang, Jayesh Mehta, Howard R. Terebelo, Cristina J. Gasparetto, Kathleen Toomey, et al. “Clinical Outcomes of Patients with Newly Diagnosed Multiple Myeloma Receiving Triplet Therapy in the Connect MM (R) Disease Registry.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Sharma, Manish, Parmeswaran Hari, Jennifer Le-Rademacher, Amrita Krishnan, Yago Nieto, Cristina Gasparetto, Jiaxing Huang, Emma C. Scott, and Anita D’Souza. “Autologous Hematopoietic Cell Transplantation in Patients with High Risk Multiple Myeloma: Post- Transplant Responses Do Not Translate to Longer Survival.” In Blood, Vol. 126. AMER SOC HEMATOLOGY, 2015.
    Link to Item
  - Gasparetto, Cristina, Michael Green, Anandgopal Srinivasan, Yubin Kang, David A. Rizzieri, Carlos Decastro, Louis F. Diehl, et al. “A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.” In Blood, 126:1857–1857. American Society of Hematology, 2015. https://doi.org/10.1182/blood.v126.23.1857.1857.
    Full Text
  - Shah, Jatin J., Rafat Abonour, Brian G. Durie, Jayesh Mehta, Mohit Narang, Howard R. Terebelo, Cristina Gasparetto, et al. “Overall survival in newly diagnosed MM patients with del(17p): A report from the Connect MM Registry.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Toomey, Kathleen, Cristina Gasparetto, Jatin J. Shah, Rafat Abonour, Jayesh Mehta, Mohit Narang, Howard R. Terebelo, et al. “Characteristics and survival of African American (AA) newly diagnosed multiple myeloma (NDMM) patients (Pts): A report from the Connect MM Registry.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Green, Michael M. B., Mitchell E. Horwitz, Yubin Kang, Nelson J. Chao, Gwynn D. Long, David Rizzieri, Cristina Gasparetto, et al. “Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial.” In Biology of Blood and Marrow Transplantation, 21:S31–32. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.024.
    Full Text
  - Liu, JoAnn, Angela Johns, and Cristina Gasparetto. “Engraftment Failure or Aplastic Anemia: A Case Report.” In Biology of Blood and Marrow Transplantation, 21:S140–41. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.195.
    Full Text
  - Bensinger, William I., Robert Vescio, Cristina Gasparetto, Elber S. Camacho, Rajneesh Nath, Christina L. Gomes, David D. Smith, Jatin J. Shah, and Brian G. M. Durie. “A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
    Link to Item
  - Cohen, Adam D., Emma C. Scott, Michaela Liedtke, Jonathan L. Kaufman, Heather Landau, David H. Vesole, Christina L. Gomes, et al. “A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
    Link to Item
  - LeBlanc, Thomas W., Cristina J. Gasparetto, Sascha A. Tuchman, Peter Sheldon, Alexandra Howson, Zeba M. Khan, Satyin Kaura, and Amy P. Abernethy. “Clinician Approaches to Myeloma in Academia and the Community : An in-Practice Qualitative Study.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
    Link to Item
  - Rifkin, Robert M., Rafat Abonour, Jatin J. Shah, Jayesh Mehta, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, et al. “Connect MM (R) the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM).” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
    Link to Item
  - Shah, Jatin J., Rafat Abonour, Brian G. M. Durie, Jayesh Mehta, Mohit Narang, Howard Terebelo, Cristina J. Gasparetto, et al. “Connect MM (R) the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
    Link to Item
  - Voorhees, Peter M., Robert L. Schlossman, Cristina J. Gasparetto, Jesus G. Berdeja, John Morris, Douglas A. Jacobstein, Kenneth C. Anderson, Constantine S. Mitsiades, Jacob P. Laubach, and Paul G. Richardson. “An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.
    Link to Item
  - D’Souza, Anita, Baldeep Wirk, Mei-Jie Zhang, Jiaxing Huang, Amrita Krishnan, Tomer M. Mark, Cristina J. Gasparetto, and Parameswaran N. Hari. “Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study.” In Blood, 124:193–193. American Society of Hematology, 2014. https://doi.org/10.1182/blood.v124.21.193.193.
    Full Text
  - LeBlanc, Thomas William, Cristina Gasparetto, Sascha Alexander Tuchman, Peter Sheldon, Alexandra Howson, Wendy Turell, Zeba M. Khan, Satyin Kaura, and Amy Pickar Abernethy. “Exploring variations in multiple myeloma management through in-practice research.” In Journal of Clinical Oncology, 32:e19534–e19534. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e19534.
    Full Text
  - Richardson, Paul G., Robert L. Schlossman, Melissa Alsina, Donna M. Weber, Steven E. Coutre, Cristina Gasparetto, Sutapa Mukhopadhyay, et al. “PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.” In Blood, 122:2331–37, 2013. https://doi.org/10.1182/blood-2013-01-481325.
    Full Text Link to Item
  - Alsina, Melissa, Paul Gerard Guy Richardson, Robert L. Schlossman, Donna M. Weber, Steven E. Coutre, Cristina Gasparetto, Sutapa Mukhopadhyay, et al. “Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Pashos, Chris L., Jatin J. Shah, Howard R. Terebelo, Brian G. Durie, Rafat Abonour, Cristina Gasparetto, Jayesh Mehta, et al. “Changes in patient-reported outcomes in patients diagnosed with and treated for multiple myeloma in the Connect MM registry.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Terebelo, Howard R., Jatin J. Shah, Brian G. Durie, Rafat Abonour, Cristina Gasparetto, Jayesh Mehta, Mohit Narang, et al. “Early mortality (EM) for newly diagnosed multiple myeloma (NDMM) in the Connect MM US registry.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Horwitz, Mitchell E., Patrick J. Stiff, Nelson J. Chao, David Rizzieri, Gwynn Long, Keith Sullivan, Cristina Gasparetto, et al. “Nicord® Expanded Hematopoietic Progenitor Cells (HPC) Are Capable of Outcompeting the Unmanipulated (UM) Cord Blood Unit and of Prolonged Myeloid and Lymphoid Engraftment Following Myeloablative Dual Umbilical Cord Blood (UCB) Transplantation.” In Biology of Blood and Marrow Transplantation, 19:S118–S118. Elsevier BV, 2013. https://doi.org/10.1016/j.bbmt.2012.11.044.
    Full Text
  - Sung, Anthony D., Julia A. M. Sung, Kelly Corbet, Vera Hars, Lan Lan, Gloria Broadwater, Ashley Zanter, et al. “Surgical Mask Usage Reduces the Incidence of Parainfleunza Virus 3 in Recipients of Stem Cell Transplantation.” In Biology of Blood and Marrow Transplantation, 19:S271–72. Elsevier BV, 2013. https://doi.org/10.1016/j.bbmt.2012.11.375.
    Full Text
  - Brander, Danielle M., Anne W. Beaven, Jon P. Gockerman, Louis F. Diehl, Cristina Gasparetto, Thomas C. Shea, Carlos deCastro, Joseph O. Moore, and David A. Rizzieri. “Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma.” In Blood, 120:1626–1626. American Society of Hematology, 2012. https://doi.org/10.1182/blood.v120.21.1626.1626.
    Full Text
  - Shah, Jatin J., Edward A. Stadtmauer, Rafat Abonour, Adam D. Cohen, William I. Bensinger, Cristina Gasparetto, Jonathan L. Kaufman, et al. “A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.
    Link to Item
  - Pashos, Chris L., Brian G. Durie, Robert M. Rifkin, Rafat Abonour, Rafael Fonseca, Cristina Gasparetto, Jayesh Mehta, et al. “Race- and health-related quality of life among patients newly diagnosed with multiple myeloma.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Rifkin, Robert M., Rafat Abonour, Rafael Fonseca, Cristina Gasparetto, Jayesh Mehta, Mohit Narang, Chris L. Pashos, et al. “Connect MM: The multiple myeloma ( MM) disease registry-Incidence of second primary malignancies (SPM).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - An, Ningfei, Yeong-Bin Im, Yingwei Lin, Cristina Gasparetto, Luciano J. Costa, Robert K. Stuart, Charles Smith, Andrew Kraft, and Yubin Kang. “Characterization of Pim Protein Kinases and Evaluation of Small Molecule Inhibitors in Multiple Myeloma.” In Blood, 118:1254–55. AMER SOC HEMATOLOGY, 2011.
    Link to Item
  - Bacon, Wendi A., Gwynn D. Long, David A. Rizzieri, Mitchell E. Horwitz, John P. Chute, Keith M. Sullivan, Amanda Yopp, Angela Johns, Nelson J. Chao, and Cristina Gasparetto. “Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma.” In Blood, 118:1765–1765. AMER SOC HEMATOLOGY, 2011.
    Link to Item
  - Gasparetto, Cristina, Wendi A. Bacon, Phuong Doan, David A. Rizzieri, Mitchell E. Horwitz, John P. Chute, Keith M. Sullivan, et al. “High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation.” In Blood, 118:879–879. AMER SOC HEMATOLOGY, 2011.
    Link to Item
  - Kanda, Junya, David A. Rizzieri, Gwynn D. Long, Cristina Gasparetto, John P. Chute, Keith M. Sullivan, Ashley Morris, et al. “The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation.” In Blood, 118:1736–1736. AMER SOC HEMATOLOGY, 2011.
    Link to Item
  - Pashos, Chris L., Brian G. M. Durie, Robert Rifkin, Howard Terebelo, Cristina Gasparetto, Jayesh Mehta, Kathleen Toomey, et al. “Variation in Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients by Insurance Coverage.” In Blood, 118:1361–62. AMER SOC HEMATOLOGY, 2011.
    Link to Item
  - Richardson, Paul G., Melissa Alsina, Donna M. Weber, Steven E. Coutre, Sagar Lonial, Cristina Gasparetto, Ghulam Warsi, et al. “Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2).” In Blood, 118:370–71. AMER SOC HEMATOLOGY, 2011.
    Link to Item
  - Voorhees, Peter M., Cristina Gasparetto, Keren Osman, Kristy L. Richards, Madlyn Ferraro, Reynaldo Garcia, Jennifer MacLean, et al. “Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study.” In Blood, 118:1705–6. AMER SOC HEMATOLOGY, 2011.
    Link to Item
  - Kanda, Junya, Gwynn D. Long, Cristina Gasparetto, Mitchell E. Horwitz, Keith M. Sullivan, John P. Chute, Ashley Morris, Zhiguo Li, Nelson J. Chao, and David A. Rizzieri. “Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies.” In Blood, 116:1456–57. AMER SOC HEMATOLOGY, 2010.
    Link to Item
  - Voorhees, Peter M., Cristina Gasparetto, Keren Osman, Kristy Richards, Madlyn Ferraro, Reynaldo Garcia, Jennifer MacLean, et al. “Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma.” In Blood, 116:815–16. AMER SOC HEMATOLOGY, 2010.
    Link to Item
  - Tuchman, Sascha, Chaitanya Acharya, William Mostertz, William Barry, Cristina Gasparetto, Bart Barlogie, Anil Potti, and John D. Shaughnessy. “Gene Expression Profiling Reveals 5-Azacytidine to Be a Novel, Potentially Effective Therapy for Poor-Prognosis Patients with Multiple Myeloma.” In Blood, 114:728–728. AMER SOC HEMATOLOGY, 2009.
    Link to Item
  - Voorhees, Peter M., Cristina Gasparetto, Kristy L. Richards, Reynaldo Garcia, John S. Strader, Madlyn Ferraro, Jennifer MacLean, et al. “Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.” In Blood, 114:129–30. AMER SOC HEMATOLOGY, 2009.
    Link to Item
  - Zonder, Jeffrey A., Vaishali Sanchorawala, Rachel M. Snyder, Jeffrey Matous, Howard Terebelo, Nalini Janakiraman, Markus Y. Mapara, et al. “Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity.” In Blood, 114:310–11. AMER SOC HEMATOLOGY, 2009.
    Link to Item
  - Kumar, Shaji, Ian W. Flinn, Stephen J. Noga, Parameswaran Hari, Robert M. Rifkin, Natalie Scott Callander, Manish Bhandari, et al. “Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II MultiCenter EVOLUTION Study.” In Blood, 112:41–42. AMER SOC HEMATOLOGY, 2008.
    Link to Item
  - Horwitz, Mitchell, John Chute, Cristina Gasparetto, Gwynn Long, David Rizzieri, Ashley Mortis, Jackie McPherson, Keith Suldivan, and Nelson Chao. “Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.” In Blood, 110:597A-598A. AMER SOC HEMATOLOGY, 2007.
    Link to Item
  - Horwitz, Mitchell, David Rizzieri, Gwynn D. Long, Cristina Gasparetto, Ashley Morris, Keith Sullivan, John Chute, Dawn Marshall, and Nelson Chao. “Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning; Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival.” In Blood, 108:5399–5399. American Society of Hematology, 2006. https://doi.org/10.1182/blood.v108.11.5399.5399.
    Full Text
  - Misra, Debashish, Joseph O. Moore, Jon P. Gockerman, Louis Diehl, Carlos de Castro, Yiping Yang, Cristina Gasparetto, et al. “Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.” In Blood, 106:4623–4623. American Society of Hematology, 2005. https://doi.org/10.1182/blood.v106.11.4623.4623.
    Full Text
  - Rizzieri, David A., Liang Piu Koh, Gwynn D. Long, Cristina Gasparetto, Jerald Z. Gong, Anand S. Lagoo, Donna Niedzwiecki, et al. “Outcome and Immune Reconstitution Following T Cell Depleted Nonmyeloablative Allogeneic Transplantation Using Matched Donors.” In Blood, 106:2036–2036. American Society of Hematology, 2005. https://doi.org/10.1182/blood.v106.11.2036.2036.
    Full Text
  - Gasparetto, Cristina, Mitchell E. Horwitz, Jon P. Gockerman, Carlos M. de Castro, Joseph O. Moore, Clay A. Smith, Patty Davis, et al. “Campath-1H May Have Activity in the Treatment of Multiple Myeloma.” In Blood, 104:4931–4931. American Society of Hematology, 2004. https://doi.org/10.1182/blood.v104.11.4931.4931.
    Full Text
  - Koh, Liang-Piu, Jon P. Gockerman, Joseph O. Moore, Carlos DeCastro, Gwynn D. Long, Cristina Gasparetto, Donna Niedzwiecki, et al. “Dose Dense, High Intensity Induction Therapy Followed by Early High Dose Chemotherapy (HDT) and Autologous Hematopoietic Stem Cell Transplantation(AHSCT) for Mantle Cell Lymphoma (MCL).” In Blood, 104:913–913. American Society of Hematology, 2004. https://doi.org/10.1182/blood.v104.11.913.913.
    Full Text
  - Wanko, Sam O., Jon P. Gocherman, Joseph O. Moore, Carlos Decastro, Robert Prosnitz, Cristina Gasparetto, John Chute, et al. “Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.” In Blood, 104:1163–1163. American Society of Hematology, 2004. https://doi.org/10.1182/blood.v104.11.1163.1163.
    Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Previous Appointments & Affiliations

Selected Grants

External Relationships

Selected Publications

Academic Articles

Conference Papers